Liquid clues: tracking early-stage breast cancer with ctDNA - a mini review

Key Points

• Circulating tumor DNA (ctDNA) may improve early detection in patients with non-metastatic breast cancer, enhancing clinical outcomes.
• Assay sensitivity advancements can facilitate monitoring treatment responses and residual disease, providing better patient care.
• Key therapeutic intervention trials integrating ctDNA into management strategies are essential for improving clinical practice in early breast cancer.
• The potential of ctDNA lies in its application for personalized medicine in early-stage breast cancer, with significant future implications.

Abstract